Kang Y Mick Form 4													
April 25, 200	1 /								OMB AI	PPROVAL			
	• • UNITE	D STATE		ITIES Al hington,			NGE (	COMMISSION	OMB Number:	3235-0287			
Check this box if no longer subject to Section 16. Form 4 or Form 5 Filed pursuant to Sectio				GES IN I SECURI	BENEFI ITIES	CIA			Expires: Estimated a burden hou response	rs per			
obligation may cont <i>See</i> Instru 1(b).	ns Section	7(a) of the		ility Hold	ing Com	ipany	Act of	f 1935 or Sectio	n				
(Print or Type I	Responses)												
Kang Y Michele S			Symbol	2. Issuer Name <b>and</b> Ticker or Trading Symbol REXAHN PHARMACEUTICALS,					5. Relationship of Reporting Person(s) to Issuer				
			INC. [R	INC. [RXHN.OB]					(Check all applicable)				
				e of Earliest Transaction h/Day/Year) 3/2008				X_ Director 10% Owner Officer (give title Other (specify below) below)					
PHARMAC	EUTICALS, I CENTER DRI		0 11 201 20										
				ndment, Date Original hth/Day/Year)				<ul> <li>6. Individual or Joint/Group Filing(Check Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting</li> </ul>					
ROCKVILI	LE, MD 20850							Person	lore than One Re	eporting			
(City)	(State)	(Zip)	Table	e I - Non-Do	erivative S	Securi	ties Acc	quired, Disposed of	f, or Beneficial	ly Owned			
1.Title of Security (Instr. 3)		asaction Date 2A. Deemed h/Day/Year) Execution Date, if any (Month/Day/Year)				spose	d of	Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)				
Common				Code V	Amount		Price	(Instr. 3 and 4)					
Common Stock	04/23/2008			Р	1,000	А	ф 2.35	1,000	D				
Common Stock	04/23/2008			Р	1,000	А	\$ 2.35	2,000	D				
Common Stock	04/23/2008			Р	1,000	А	\$ 2.35	3,000	D				
Common Stock	04/23/2008			Р	1,000	А	\$ 2.35	4,000	D				
	04/23/2008			Р	1 000	А	\$23	5 000	D				

Common Stock							
Common Stock	04/23/2008	Р	2,500	А	\$ 2.3	7,500	D
Common Stock	04/23/2008	Р	500	А	\$ 2.25	8,000	D
Common Stock	04/24/2008	Р	500	А	\$ 2.35	8,500	D
Common Stock	04/24/2008	Р	1,500		\$ 2.35		D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	;	ate	7. Title Amou Under Securi (Instr.	nt of lying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owne Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

## **Reporting Owners**

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
Kang Y Michele C/O REXAHN PHARMACEUTICALS, INC. 9620 MEDICAL CENTER DRIVE ROCKVILLE, MD 20850	Х					

## Signatures

Tae Heum Jeong for Y. Michele Kang

04/25/2008

Date

\*\*Signature of Reporting Person

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.